KRAS and neoplasm: Elevated expression of VISTA on T cells, MDSCs and TAMs are associated with oncogenic KRAS-driven tumours [109] and resistance to anti-PD-1 by ICB [110, 111], identifying VISTA as a promising immunotherapy target.